Adaptive immunity in rheumatoid arthritis: Anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 72-79

  Klareskog, Lars ^a   Amara, Khaled ^a   Malmström, Vivianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

anticitrulline protein antibodies; cartilage derived autoantigens; immunotherapy; posttranslational modifications

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CITRULLINATED PROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS;

ADAPTIVE IMMUNITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; CITRULLINE; CROSS REACTIONS; HUMANS; PEPTIDES, CYCLIC;

EID: 84890258442     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000016     Document Type: Review

References (53)

1. Kollias G, Papadaki P, Apparailly F, et al. Animal models for arthritis: Innovative tools for prevention and treatment. Ann Rheum Dis 2011; 70:1357- 1362.
2. Monach P, Hattori K, Huang H, et al. The K/BxN mouse model of inflammatory arthritis: Theory and practice. Methods Mol Med 2007; 136:269-282.
3. Carlsen S, Lu S, Holmdahl R. Arthritis induced with minor cartilage proteins. Methods Mol Med 2007; 136:225-242.
4. Uysal H, Bockermann R, Nandakumar KS, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med 2009; 206:449-462.
5. Bas DB, Su J, Sandor K, et al. Collagen antibody-induced arthritis evokes persistent pain with spinal glial involvement and transient prostaglandin dependency. Arthritis Rheum 2012; 64:3886-3896.
6. Harre U, Georgess D, Bang H, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122:1791-1802.
7. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-281.
8. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. J Immunol 1999; 162:585- 594.
9. Klareskog L, Rö nnelid J, Lundberg K, et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008; 26:651-675.
10. Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010; 62:44-52.
11. Shoda H, Fujio K, Shibuya M, et al. Detection of autoantibodies to citrullinatedBiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 2011; 13:R191.
12. Goules JD, Goules AV, Tzioufas AG. Fine specificity of anticitrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis. Clin Exp Immunol 2013; 174:10-17.
13. Pratesi F, Dioni I, Tommasi C, et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann Rheum Dis 2013. [Epub ahead or print].
14. Umeda N, Matsumoto I, Ito I, et al. Anticitrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity. Clin Exp Immunol 2013; 172:44-53.
15. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol 2010; 6: 727-730.
16. Quirke AM, Lugli EB, Wegner N, et al. Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: A potential mechanism for breaching immunologic tolerance in rheumatoid arthritis. Ann Rheum Dis 2013. [Epub ahead or print].
17. Shi J, Willemze A, Janssen GM, et al. Recognition of citrullinated and carbamylated proteins by human antibodies: Specificity, cross-reactivity and the 'AMC-Senshu' method. Ann Rheum Dis 2013; 72:148-150.
18. Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 2013; 72:652-658.
19. Strollo R, Ponchel F, Malmström V, et al. Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis Rheum 2013; 65:1702-1712.
20. Aho K, von Essen R, Kurki P, et al. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol 1993; 20:1278-1281.
21. Shi J, van de Stadt LA, Levarht EW, et al. Anticarbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 2013; 65:911-915.
22. Rö nnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005; 64:1744- 1749.
23. van de Stadt LA, de Koning MH, van de Stadt RJ, et al. Development of the anticitrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum 2011; 63:3226-3233.
24. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the preclinical phase predicts progression to rheumatoid arthritis. PLoS One 2012; 7:e35296.
25. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013; 65:899-910.
26. van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis 2013; 72:1920-1926.
27. de Hair MJ, Landewé RB, van de Sande MG, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 2012; 72:1654-1658.
28. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
29. Klareskog L, Lundberg K, Malmström V. Autoimmunity in rheumatoid arthritis: Citrulline immunity and beyond. Adv Immunol 2013; 118:129- 158.
30. Reynisdottir G, Karimi R, Joshua V, et al. Structural lung changes and local anticitrulline immunity are early features of anti citrullinated-proteins antibodies (ACPA)-positive rheumatoid arthritis. Arthritis Rheum. [Epub ahead of print]
31. Bang SY, Lee HS, Lee KW, Bae SC. Interaction of HLA-DRB1-09:01 and -04:05 with smoking suggests distinctive mechanisms of rheumatoid arthritis susceptibility beyond the shared epitope. J Rheumatol 2013; 40:1054- 1062.
32. Darrah E, Giles JT, Ols ML, et al. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med 2013; 5:185ra65.
33. Snir O, Rieck M, Gebe JA, et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1-0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011; 63:2873-2883.
34. Ireland JM, Unanue ER. Processing of proteins in autophagy vesicles of antigen-presenting cells generates citrullinated peptides recognized by the immune system. Autophagy 2012; 8:429-430.
35. Sollid LM, Jabri B. Triggers and drivers of autoimmunity: Lessons from coeliac disease. Nat Rev Immunol 2013; 13:294-302.
36. Pitzalis C, Kelly S, Humby F. New learnings on the pathophysiology of RA from synovial biopsies. Curr Opin Rheumatol 2013; 25:334-344.
37. Amara K, Steen J, Murray F, et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J Exp Med 2013; 210:445-455.
38. Lundberg K, Nijenhuis S, Vossenaar ER, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005; 7:R458- R467.
39. Thiele GM, Duryee MJ, Dusad A, et al. Citrullinated mouse collagen administered to DBA/1J mice in the absence of adjuvant initiates arthritis. Int Immunopharmacol 2012; 13:424-431.
40. Nandakumar KS, Bajtner E, Hill L, et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum 2008; 58:184- 196.
41. Hill JA, Bell DA, Brintnell W, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008; 205:967-979.
42. Kinloch AJ, Alzabin S, Brintnell W, et al. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian a-enolase and arthritis in DR4-IE-transgenic mice. Arthritis Rheum 2011; 63:3818-3823.
43. Kuhn KA, Kulik L, Tomooka B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006; 116:961-973.
44. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, et al. NETs are a source of citrullinatedautoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med 2013; 5.
45. Li P, Li M, Lindberg MR, et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 2010; 207:1853-1862.
46. Sokolove J, Zhao X, Chandra PE, et al. Immune complexes containing citrullinated fibrinogen costimulate macrophages via toll-like receptor 4 and Fcg receptor. Arthritis Rheum 2011; 63:53-62.
47. Eloranta ML, Alm GV, Rö nnblom L. Disease mechanisms in rheumatology: Tools and pathways - plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases. Arthritis Rheum 2013; 65:853-863.
48. Chirivi RGS, Jenniskens GJ, Raats JMH. Anticitrullinated protein antibodies as novel therapeutic drugs in rheumatoid arthritis. J Clin Cell Immunol 2013; S6:006.
49. Collin M, Shannon O, Bjö rck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci U S A 2008; 105:4265-4270.
50. Nandakumar KS, Collin M, Happonen KE, et al. Dominant suppression of inflammation by glycan-hydrolyzed IgG. Proc Natl Acad Sci U S A 2013; 110:10252-10257.
51. Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, et al. Evidence for a functional role of IgEanticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci U S A 2010; 107:2586-2591.
52. Svärd A, Kastbom A, Sommarin Y, Skogh T. Salivary IgA antibodies to cyclic citrullinated peptides (CCP) in rheumatoid arthritis. Immunobiology 2013; 218:232-237.
53. Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: Report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012; 71:638-641.